X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3692) 3692
Book Review (768) 768
Publication (361) 361
Book Chapter (27) 27
Book / eBook (9) 9
Conference Proceeding (9) 9
Magazine Article (8) 8
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3036) 3036
alzheimer's disease (2151) 2151
humans (2144) 2144
animals (2057) 2057
neurosciences (1578) 1578
mice (1305) 1305
alzheimers-disease (1013) 1013
alzheimer disease - pathology (1010) 1010
amyloid beta-peptides - metabolism (1003) 1003
alzheimer disease - metabolism (951) 951
brain (927) 927
male (913) 913
mice, transgenic (897) 897
plaques (877) 877
disease models, animal (846) 846
female (764) 764
plaque, amyloid - pathology (715) 715
plaque, amyloid - metabolism (669) 669
transgenic mice (651) 651
alzheimer disease - drug therapy (636) 636
brain - pathology (590) 590
brain - metabolism (583) 583
alzheimers disease (581) 581
neurodegenerative diseases (557) 557
senile plaques (549) 549
pathology (515) 515
a-beta (508) 508
neurology (478) 478
amyloid precursor protein (467) 467
amyloid (458) 458
dementia (458) 458
inflammation (456) 456
aged (452) 452
amyloid beta-protein precursor - genetics (451) 451
biochemistry & molecular biology (451) 451
proteins (446) 446
alzheimer disease - genetics (443) 443
alzheimer’s disease (429) 429
mouse model (396) 396
clinical neurology (393) 393
alzheimer disease - physiopathology (383) 383
in-vivo (382) 382
oxidative stress (381) 381
neurofibrillary tangles (379) 379
rats (355) 355
mice, inbred c57bl (353) 353
neurodegeneration (350) 350
brain - drug effects (349) 349
amyloid beta-protein precursor - metabolism (346) 346
β-amyloid (333) 333
rodents (332) 332
analysis (331) 331
peptides (311) 311
amyloid beta-protein (308) 308
protein (307) 307
microglia (296) 296
amyloid-beta (291) 291
memory (280) 280
cells, cultured (277) 277
cognitive ability (277) 277
pharmacology & pharmacy (276) 276
article (274) 274
cell biology (272) 272
precursor protein (270) 270
amyloid plaques (265) 265
peptide fragments - metabolism (265) 265
middle aged (262) 262
aged, 80 and over (257) 257
research (255) 255
disease (254) 254
neurons (253) 253
multidisciplinary sciences (250) 250
alzheimer disease (243) 243
mild cognitive impairment (236) 236
medicine (234) 234
neurons - metabolism (234) 234
tau proteins - metabolism (234) 234
aging (230) 230
geriatrics & gerontology (226) 226
neurons - drug effects (219) 219
plaque-formation (219) 219
hippocampus (216) 216
immunohistochemistry (214) 214
mutation (205) 205
physiological aspects (204) 204
expression (203) 203
tau (202) 202
research article (201) 201
central-nervous-system (200) 200
risk factors (200) 200
phosphorylation (198) 198
dose-response relationship, drug (196) 196
peptide (196) 196
hippocampus - metabolism (188) 188
pathogenesis (187) 187
animal models (185) 185
neurotoxicity (185) 185
tau protein (182) 182
neurons - pathology (181) 181
hippocampus - pathology (179) 179
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3712) 3712
German (5) 5
French (4) 4
Chinese (3) 3
Russian (2) 2
Dutch (1) 1
Japanese (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 08/2016, Volume 537, Issue 7618, pp. 50 - 56
Journal Article
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 05/2006, Volume 26, Issue 20, pp. 5340 - 5346
Systemic administration of anti-amyloid-beta (A beta) antibodies results in reduced parenchymal amyloid but increased vascular amyloid and microhemorrhage in... 
CAA | Microhemorrhage | Immunotherapy | Vaccination | Alzheimer's | Microglia | RECOGNITION | ALZHEIMERS-DISEASE | MEMORY DEFICITS | microhemorrhage | PATHOLOGY | NEUROSCIENCES | PEPTIDE | IMMUNIZATION | ENCEPHALITIS | immunotherapy | MOUSE MODEL | NEUROPATHOLOGY | microglia | vaccination | Memory Disorders - physiopathology | Immunotherapy - methods | Blood Vessels - metabolism | Blood Vessels - pathology | Memory Disorders - metabolism | Plaque, Amyloid - drug effects | Brain - metabolism | Cerebral Arterial Diseases - prevention & control | Cognition Disorders - prevention & control | Alzheimer Disease - prevention & control | Amyloid beta-Peptides - metabolism | Amyloid beta-Protein Precursor - metabolism | Cerebral Arterial Diseases - physiopathology | Disease Models, Animal | Antibodies - therapeutic use | Alzheimer Disease - physiopathology | Cognition Disorders - physiopathology | Maze Learning - physiology | Brain - physiopathology | Alzheimer Disease - drug therapy | Mice, Transgenic | Treatment Outcome | Glycosylation | Cognition Disorders - drug therapy | Down-Regulation - drug effects | Maze Learning - drug effects | Aging - pathology | Plaque, Amyloid - genetics | Antibodies - pharmacology | Brain - drug effects | Down-Regulation - physiology | Amyloid beta-Peptides - antagonists & inhibitors | Amyloid beta-Protein Precursor - genetics | Animals | Memory Disorders - drug therapy | Blood Vessels - drug effects | Cerebral Arterial Diseases - drug therapy | Plaque, Amyloid - metabolism | Mice | Aging - metabolism | Index Medicus | Alzheimer’s
Journal Article
Neuroscience, ISSN 0306-4522, 2006, Volume 144, Issue 3, pp. 950 - 960
Abstract Vaccination with Aβ1–42 and treatment with NCX-2216, a novel nitric oxide releasing flurbiprofen derivative, have each been shown separately to reduce... 
Neurology | cerebral amyloid angiopathy | Alzheimer’s disease | inflammation | microglia | immunotherapy | Alzheimer's disease | MICROGLIAL ACTIVATION | ALZHEIMERS-DISEASE | PATHOLOGY | NEUROSCIENCES | PEPTIDE | IMMUNIZATION | IMMUNE-RESPONSES | MOUSE MODEL | PRECURSOR-PROTEIN | PPAR-GAMMA | TRANSGENIC MICE | Cerebral Amyloid Angiopathy - immunology | Amyloid beta-Peptides - pharmacology | Peptide Fragments - pharmacology | Plaque, Amyloid - drug effects | Cerebral Hemorrhage - immunology | Cerebral Hemorrhage - physiopathology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Brain - metabolism | Cerebral Arteries - drug effects | Cerebral Amyloid Angiopathy - chemically induced | Vaccination - methods | Peptide Fragments - immunology | Drug Therapy, Combination | Flurbiprofen - analogs & derivatives | Cerebral Hemorrhage - chemically induced | Alzheimer Disease - physiopathology | Plaque, Amyloid - pathology | Cerebral Amyloid Angiopathy - physiopathology | Brain - physiopathology | Alzheimer Disease - drug therapy | Presenilin-1 - genetics | Cerebral Arteries - physiopathology | Mice, Transgenic | Treatment Outcome | Metabolic Clearance Rate - physiology | Brain - drug effects | Amyloid beta-Protein Precursor - genetics | Animals | Cerebral Arteries - metabolism | Alzheimer Disease - metabolism | Amyloid beta-Peptides - immunology | Plaque, Amyloid - metabolism | Metabolic Clearance Rate - drug effects | Mice | Flurbiprofen - pharmacology | Index Medicus
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 02/2005, Volume 25, Issue 8, pp. 1904 - 1913
Alzheimer's disease ( AD) is characterized by enhanced beta amyloid peptide ( betaA) deposition along with glial activation in senile plaques, selective... 
Neuroprotection | Cannabinoids | Neurotoxicity | Alzheimer's disease | β-amyloid | Microglia | SELECTIVE ANTAGONIST | HUMAN BRAIN | MESSENGER-RNA EXPRESSION | NITRIC-OXIDE SYNTHASE | NEUROSCIENCES | beta-amyloid | CB2 RECEPTORS | neurotoxicity | neuroprotection | AMYLOID-BETA-PEPTIDE | IN-VIVO | cannabinoids | PRECURSOR PROTEIN | microglia | RECEPTOR-BINDING | TRANSGENIC MICE | Tumor Necrosis Factor-alpha - metabolism | Microglia - metabolism | Receptor, Cannabinoid, CB2 - physiology | Rats, Wistar | Receptor, Cannabinoid, CB2 - agonists | Peptide Fragments - toxicity | Cells, Cultured - cytology | Coculture Techniques | Humans | Middle Aged | Injections, Intraventricular | Motor Activity - drug effects | Male | Benzoxazines | Plaque, Amyloid - drug effects | Receptor, Cannabinoid, CB1 - physiology | Microglia - physiology | Neuroprotective Agents - pharmacology | Receptor, Cannabinoid, CB1 - agonists | Protein Processing, Post-Translational - drug effects | Alzheimer Disease - prevention & control | Nerve Degeneration - prevention & control | Dronabinol - analogs & derivatives | Amyloid beta-Peptides - metabolism | Neurons - physiology | Female | Dronabinol - pharmacology | Neurons - drug effects | Neuroprotective Agents - administration & dosage | Alzheimer Disease - physiopathology | Cells, Cultured - drug effects | Microglia - drug effects | Amyloid beta-Peptides - toxicity | Cannabinoids - administration & dosage | Morpholines - administration & dosage | Cells, Cultured - physiology | Morpholines - pharmacology | Rats | Maze Learning - drug effects | Cannabinoids - pharmacology | Naphthalenes - pharmacology | Animals | Signal Transduction - drug effects | Naphthalenes - administration & dosage | Plaque, Amyloid - metabolism | Aged | Nitric Oxide - metabolism | Index Medicus | Neurobiology of Disease
Journal Article
Brain, ISSN 0006-8950, 05/2010, Volume 133, Issue 5, pp. 1342 - 1351
Reduction of glucose metabolism in brain is one of the main features of Alzheimer's disease. Thiamine (vitamin B1)-dependent processes are critical in glucose... 
Glycogen synthase kinase-3 | Alzheimer's disease | Benfotiamine | Thiamine | OXIDATIVE STRESS | PROTEIN | ALZHEIMERS-DISEASE | PHOSPHATE-ESTERS | RISK | NEUROSCIENCES | CLINICAL NEUROLOGY | benfotiamine | glycogen synthase kinase-3 | POSITRON-EMISSION-TOMOGRAPHY | thiamine | THIAMINE-DEFICIENCY | DERIVATIVES | BRAIN | HYPERGLYCEMIC DAMAGE | Memory - drug effects | tau Proteins - metabolism | Cognition Disorders - metabolism | Plaque, Amyloid - drug effects | Cerebral Cortex - metabolism | Alzheimer Disease - pathology | Brain - metabolism | Dose-Response Relationship, Drug | Amyloid beta-Peptides - genetics | Isoenzymes - metabolism | Cognition Disorders - etiology | Amyloid beta-Peptides - metabolism | Swimming | Phosphorylation - drug effects | Alzheimer Disease - psychology | Cognition Disorders - psychology | Drug Administration Schedule | Plaque, Amyloid - pathology | Presenilin-1 - genetics | Mice, Transgenic | Cognition - drug effects | Thiamine - analogs & derivatives | Thiamine - metabolism | Amyloid beta-Peptides - antagonists & inhibitors | Animals | Maze Learning | Fursultiamin - pharmacology | Glycogen Synthase Kinases - antagonists & inhibitors | Presenilin-1 - metabolism | Alzheimer Disease - metabolism | Thiamine - administration & dosage | Mice | Alzheimer Disease - genetics | Glycogen Synthase Kinases - metabolism | Isoenzymes - antagonists & inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Neurochemistry, ISSN 0022-3042, 03/2009, Volume 108, Issue 5, pp. 1198 - 1207
Journal Article
Neuroscience, ISSN 0306-4522, 2009, Volume 163, Issue 1, pp. 55 - 72
Abstract Granulocyte colony stimulating factor (G-CSF) is a multi-modal hematopoietic growth factor, which also has profound effects on the diseased CNS. G-CSF... 
Neurology | synaptophysin | neurogenesis | hippocampus | microglia | bone marrow | β-amyloid | FOCAL CEREBRAL-ISCHEMIA | BONE-MARROW | MICROGLIAL CELLS | NEUROSCIENCES | HEMATOPOIETIC GROWTH-FACTORS | beta-amyloid | A-BETA DEPOSITION | MARROW-DERIVED CELLS | ENRICHMENT IMPROVES COGNITION | MOUSE MODEL | FACTOR G-CSF | TRANSGENIC MICE | Neuroprotective Agents - therapeutic use | Entorhinal Cortex - metabolism | S100 Calcium Binding Protein G - drug effects | Humans | Cognition Disorders - metabolism | Hippocampus - drug effects | Plaque, Amyloid - drug effects | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Cell Movement - immunology | Entorhinal Cortex - physiopathology | Encephalitis - physiopathology | Microglia - physiology | Neuroprotective Agents - pharmacology | Dentate Gyrus - drug effects | Encephalitis - drug therapy | Encephalitis - metabolism | Neurogenesis - drug effects | Disease Models, Animal | Synaptophysin - metabolism | Green Fluorescent Proteins - metabolism | Alzheimer Disease - physiopathology | Cognition Disorders - physiopathology | Dentate Gyrus - metabolism | Cytokines - metabolism | Microglia - drug effects | Alzheimer Disease - drug therapy | Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology | Mice, Transgenic | Entorhinal Cortex - drug effects | Cognition Disorders - drug therapy | S100 Calcium Binding Protein G - metabolism | Cell Movement - drug effects | Hippocampus - metabolism | Animals | Calbindin 2 | Cytokines - drug effects | Neurogenesis - physiology | Alzheimer Disease - metabolism | Plaque, Amyloid - metabolism | Mice | Hippocampus - physiopathology | Synaptophysin - drug effects | Phosphates | Brain | Neurosciences | Biological response modifiers | Hematopoietic stem cells | Stem cell research | Mobilization | Colony-stimulating factors (Physiology) | Armed Forces | Analysis | Universities and colleges | Alzheimer's disease | Interferon gamma | Index Medicus
Journal Article
Neuroscience Letters, ISSN 0304-3940, 2009, Volume 455, Issue 3, pp. 187 - 190
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 11/2001, Volume 21, Issue 21, pp. 8370 - 8377
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 05/2008, Volume 28, Issue 20, pp. 5149 - 5158
Journal Article
Neuroscience Letters, ISSN 0304-3940, 03/2009, Volume 452, Issue 2, pp. 90 - 95
Journal Article
Neurology, ISSN 0028-3878, 11/2006, Volume 67, Issue 10, pp. 1757 - 1763
Background: As a potential disease-modifying treatment for Alzheimer disease ( AD), 3-amino-1-propanesulfonic acid (3APS) is a compound that binds to amyloid... 
GAMMA-SECRETASE INHIBITOR | CENT